Revenue has contracted significantly to $1.1M in 2026Q1, while negative operating leverage has pushed operating margins to a concerning -153.8%.
| Sales/Revenue | 5.38M | 5.72M | 6.56M | 13.2M | 22.77M |
| Revenue Growth % | -13.54% | -12.8% | -50.29% | -42.01% | - |
| Cost of Goods Sold | 3.46M | 3.62M | 4M | 7.55M | 13.32M |
| COGS % of Revenue | - | 63.23% | 60.95% | 57.21% | 58.49% |
| Gross Profit | 1.92M | 2.1M | 2.56M | 5.65M | 9.45M |
| Gross Margin % | 35.66% | 36.77% | 39.05% | 42.79% | 41.51% |
| Gross Profit Growth % | - | -17.9% | -54.63% | -40.23% | - |
| Operating Expenses | 8.87M | 8.6M | 4.84M | 3.45M | 3.15M |
| OpEx % of Revenue | - | 150.21% | 73.71% | 26.11% | 13.85% |
| Selling, General & Admin | 8.87M | 8.6M | 4.64M | 3.33M | 3.15M |
| SG&A % of Revenue | - | 150.21% | 70.75% | 25.22% | 13.85% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 194.69K | 116.95K | 0 |
| Operating Income | -6.95M | -6.49M | -2.27M | 2.2M | 6.3M |
| Operating Margin % | -129.21% | -113.44% | -34.66% | 16.68% | 27.66% |
| Operating Income Growth % | - | -185.41% | -203.3% | -65.03% | - |
| EBITDA | -6.8M | -6.34M | -2.13M | 2.3M | 6.37M |
| EBITDA Margin % | -126.39% | -110.79% | -32.47% | 17.46% | 27.96% |
| EBITDA Growth % | -107.2% | -197.52% | -192.46% | -63.79% | - |
| D&A (Non-Cash Add-back) | 151.47K | 151.95K | 143.69K | 102.8K | 68.49K |
| EBIT | -8.43M | -7.97M | -2.26M | 2.2M | 6.3M |
| Net Interest Income | 5.76K | 6.02K | 6.53K | 2.04K | -6.12K |
| Interest Income | 8.38K | 8.69K | 11.9K | 2.04K | 0 |
| Interest Expense | 2.61K | 2.67K | 5.37K | 0 | 6.12K |
| Other Income/Expense | -2.99M | -1.48M | 6.53K | 2.04K | -1.62K |
| Pretax Income | -9.94M | -7.97M | -2.27M | 2.2M | 6.3M |
| Pretax Margin % | -184.83% | -139.25% | -34.56% | 16.69% | 27.65% |
| Income Tax | -7.02K | -2.96K | 25.37K | 23K | 75K |
| Effective Tax Rate % | 0.07% | 0.04% | -1.12% | 1.04% | 1.19% |
| Net Income | -9.94M | -7.97M | -2.29M | 2.18M | 6.22M |
| Net Margin % | -184.7% | -139.19% | -34.95% | 16.52% | 27.32% |
| Net Income Growth % | -187.6% | -247.32% | -205.16% | -64.94% | - |
| Net Income (Continuing) | -9.94M | -7.97M | -2.29M | 2.18M | 6.22M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.82 | -1.82 | -0.87 | 0.44 | 1.24 |
| EPS Growth % | -76.33% | -109.2% | -297.73% | -64.52% | - |
| EPS (Basic) | - | -1.82 | -0.87 | 0.44 | 1.24 |
| Diluted Shares Outstanding | 5.45M | 4.38M | 2.63M | 5M | 5M |
| Basic Shares Outstanding | 5.45M | 4.38M | 2.63M | 5M | 5M |
| Dividend Payout Ratio | - | - | - | 339.13% | 71.45% |
Insufficient scale and liquidity
As evidenced by the most recent quarterly data, Callan JMB Inc. has experienced a sustained revenue decline, with the top line falling to $1.1M in 2026Q1, representing a significant contraction from the $2.0M peak observed in 2024Q2, suggesting potential challenges in maintaining clinical trial client retention.
The consistent downward trajectory in revenue suggests that the company's specialized logistics services are struggling to gain traction within the competitive life sciences sector. This decline may indicate that the firm is losing market share to larger, more established cold-chain providers or that the underlying clinical trial cycles are experiencing unexpected delays.
Based on reported financial statements, gross margins have fluctuated significantly, ranging from a low of 24.7% in 2023Q4 to a high of 48.5% in 2024Q2, highlighting the inherent difficulty in maintaining pricing power within the highly specialized and competitive ultra-low temperature transport market.
The volatility in gross margins suggests that the company lacks the pricing power necessary to consistently pass through the costs of specialized materials and regulatory compliance. Investors should monitor whether the recent compression toward 38.6% in 2026Q1 reflects a permanent shift in the competitive landscape or merely temporary fluctuations in shipment mix.
According to recent SEC filings, the company's operating margin has deteriorated to -153.8% in 2026Q1, demonstrating a clear case of negative operating leverage where fixed SG&A costs are failing to scale against a shrinking revenue base, further pressuring the firm's limited cash reserves.
The inability to align SG&A expenses with declining revenue suggests that the company's current cost structure is misaligned with its operational scale. This persistent operating loss indicates that the business model may require a fundamental restructuring to achieve the density required for profitability.
Analysis of the income statement reveals that SG&A expenses have remained stubbornly high, often exceeding $2M per quarter, which, when compared to the $1.1M revenue reported in 2026Q1, underscores a critical lack of expense discipline relative to the company's current operational output.
The high fixed-cost base appears to be a significant drag on performance, as the company continues to incur substantial overhead despite the lack of top-line growth. Without a clear path to reducing these fixed obligations, the company may continue to face significant pressure on its bottom line.
As reported in financial statements, the company's cash position of $2.1M, when viewed against the backdrop of consistent quarterly operating losses exceeding $1.5M, suggests that the firm's runway is rapidly diminishing, warranting further investigation into potential future financing needs or dilutive capital raises.
Short-sellers would likely focus on the widening gap between cash burn and revenue generation, which suggests that the current business model is not self-sustaining. The lack of a clear inflection point in the operating results implies that the company may be forced to seek external capital under unfavorable terms.
Quick answers to the most common questions about buying CJMB stock.
For fiscal year 2025, Callan JMB Inc. (CJMB) reported total revenue of $5.7M. This represents a 74.9% decline compared to $22.8M in 2022.
Callan JMB Inc. (CJMB) reported a net loss of $8.0M for the fiscal year ending 2025.
Callan JMB Inc. (CJMB) reported an operating income of $-6.5M, resulting in an operating profit margin of -113.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Callan JMB Inc. (CJMB) generated $2.1M in gross profit for the year, representing a gross profit margin of 36.8%. This demonstrates the company's core pricing power and production efficiency.